Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease

  • M. Santin
  • M. Mestre
  • E. Shaw
  • M. J. Barbera
  • A. Casanova
  • J. Niubo
  • F. Bolao
  • D. Podzamczer
  • F. Gudiol
Article

Abstract

The effect of coinfection with hepatitis C virus (HCV) on immune restoration in 39 human immunodeficiency virus (HIV)-infected patients during treatment with combined antiretroviral therapy (cART) was prospectively evaluated. After 48 weeks of treatment, HCV-coinfected patients had lower increases in CD4% (P = .05), total CD4+ (P = .01), and naïve CD4+ (P = .06) T cells than did single-infected subjects. Higher baseline naïve CD4+ T-cell levels were associated with better CD4+ (P = .05) and naïve CD4+ (P < .001) T-cell recovery. After a 4-year follow up, the differences disappeared (median CD4+ increase: 291 and 306 cells for HCV-positive and HCV-negative patients, respectively, P = .9). No significant differences were seen in memory CD4+ T cells (P = .30), and CD8+ cells expressing CD38 (P = .10) and CD28 (P = .73). These results suggest that, independently of other factors, infection with HCV blunts early CD4+ T-cell recovery in HIV-infected patients treated with combined antiretroviral therapy (cART). However, as good control of viral replication is maintained, satisfactory long-term immune restoration can nonetheless be achieved.

References

  1. 1.
    Sabin CA, Telfer P, Phillips AN, Bhagani S, Lee CA (1997) The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 175:164–168PubMedGoogle Scholar
  2. 2.
    Piroth L, Duong M, Quantin C, Abrahamowicz M, Michardiere R, Aho LS, Grappin M, Buisson M, Waldner A, Portier H, Chavenet P (1998) Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 12:381–388CrossRefPubMedGoogle Scholar
  3. 3.
    Greub G, Lederberger B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, Erb P, Boggian K, Piffaretti JC, Hirschel B, Janin P, Francioli P, Flepp M, Telenti A (2000) Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus co-infection: the Swiss HIV cohort study. Lancet 356:1800–1805CrossRefPubMedGoogle Scholar
  4. 4.
    De Luca A, Bugarini R, Cozzi Lepri A, Puoti M, Girardi E, Antinori A, Poggio A, Pagano G, Tositti G, Cadeo G, Macor A, Toti M, D’Arminio Monforte A, Italian Naïve Antiretrovirals Study Group (2002) Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naïve HIV-infected subjects. Arch Intern Med 162:2125–132CrossRefPubMedGoogle Scholar
  5. 5.
    Macias J, Pineda JA, Leal M, Abad MA, Garcia-Pesquera F, Delgado J, Gallardo JA, Sanchez-Quijano A, Lissen E (1998) Influence of hepatitis C virus infection on the mortality of antiretroviral-treated patients with HIV disease. Eur J Clin Infect Dis 17:167–170CrossRefGoogle Scholar
  6. 6.
    Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL (2002) Hepatitis C and progression of HIV disease. JAMA 288:199–206CrossRefPubMedGoogle Scholar
  7. 7.
    Martin C, Castilla J, Lopez M, Arranz R, Gonzalez-Lahoz J, Soriano V (2004) Impact of chronic hepatitis C on HIV-1 disease progression. HIV Clin Trials 5:125–131CrossRefGoogle Scholar
  8. 8.
    Lincoln D, Petoumenos K, Dore GJ, on behalf of the Australian HIV Observational Database (2003) HIV/HBV and HIV/HCV coinfection and outcomes following highly active antiretroviral therapy. HIV Med 4:241–249CrossRefPubMedGoogle Scholar
  9. 9.
    Chung RT, Evans SR, Yang Y, Theodore D, Valdez H, Clark R, Shikuma C, Nevin T, Sherman KE, AIDS Clinical Trials Group 383 Study Team (2002) Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 16:1915–1923CrossRefPubMedGoogle Scholar
  10. 10.
    Miller MF, Haley C, Koziel MJ, Rowley CF (2005) Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis 41:713–720CrossRefPubMedGoogle Scholar
  11. 11.
    Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debré P, Leibowitch J (1997) Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112–116CrossRefPubMedGoogle Scholar
  12. 12.
    Plana M, Ferrer E, Martinez C, Podzamczer D, Garcia F, Maleno MJ, Barcelo JJ, Garcia A, Barbera MJ, Lacarcel M, Miro JC, Gallart, Gatell JM (2004) Immune restoration in HIV-positive, antiretroviral-naïve patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine. Antivir Ther 9:197–204PubMedGoogle Scholar
  13. 13.
    Mestre M, González C, Griñó JM, Valls A, Bonete J, Mane E, Corominas M, Bas J, Romeu A, Buendia E (1992) Sequential monitoring of immunoregulatory T cell subsets in renal transplantation. Transplant Proc 24:73–75PubMedGoogle Scholar
  14. 14.
    Michael CG, Kirk O, Mathiesen L, Nielsen SD (2002) The naïve CD4+ count in HIV-infected patients at time of initiation of highly active antiretroviral therapy is strongly associated with the level of immunological recovery. Scand J Infect Dis 34:45–49CrossRefPubMedGoogle Scholar
  15. 15.
    Mildvan D, Bosch RJ, Kim RS, Spritzler J, Haas DW, Kuritzkes D, Kagan J, Nokta M, DeGruttola V, Moreno M, Landay A (2004) Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis 89:1811–1820CrossRefGoogle Scholar
  16. 16.
    Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, the Swiss HIV Cohort Study (2005) Characteristics, determinats, and clinical relevance of CD4 T cell recovery to <500 cells/μL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 41:361–372CrossRefPubMedGoogle Scholar
  17. 17.
    Voirin N, Trepo C, Esteve J, Chevallier P, Ritter J, Fabry J, Vanhems P (2002) Effects of co-infection with hepatitis C virus and GB virus C on CD4 cell count and HIV-RNA level among HIV-infected patients treated with highly active antiretroviral therapy. AIDS 16:1556–1559CrossRefPubMedGoogle Scholar
  18. 18.
    Rodriguez B, Woolley I, Lederman MM, Zdunek D, Hess G, Valdez H (2003) Effect of GB virus coinfection on response to antiretroviral treatment in human immunodeficiency virus-infected patients. J Infect Dis 187:504–507CrossRefPubMedGoogle Scholar
  19. 19.
    Macias J, Pineda JA, Lozano F, Corzo JE, Ramos A, Leon E, Garcia-Garcia JA, Fernandez-Rivera J, Mira JA, Gomez-Mateos J (2003) Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naïve patients coinfected with human immunodeficiency virus and hepatitis C virus. Eur J Clin Microbiol Infect Dis 22:675–680CrossRefPubMedGoogle Scholar
  20. 20.
    Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA, Dore GJ (2004) Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 18:1169–1177CrossRefPubMedGoogle Scholar
  21. 21.
    Lerat H, Berby F, Trabaud MA, Vidalin O, Major M, Trepo C, Inchauspe G (1996) Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. J Clin Invest 97:845–851PubMedCrossRefGoogle Scholar
  22. 22.
    Radkowski M, Wang LF, Vargas H, Rakela J (1998) The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1. J Infect Dis 178:1189–1192PubMedGoogle Scholar
  23. 23.
    Lucas GM, Cheever LW, Chaisson RE, Moore RD (2001) Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 27:251–259PubMedGoogle Scholar
  24. 24.
    Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV (1997) Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of HIV disease progression to AIDS and death in the multicenter AIDS cohort study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 16:83–92PubMedGoogle Scholar
  25. 25.
    Carbone J, Gil J, Benito JM, Navarro J, Muñoz-Fernandez A, Bartolome J, Zabay JM, Lopez F, Fernandez-Cruz E (2000) Increased levels of activated subsets of CD4 T cells add to the prognostic value of low CD4 T cell counts in a cohort of HIV-infected drug users. AIDS 14:2823–2829CrossRefPubMedGoogle Scholar
  26. 26.
    Anthony KB, Yoder Ch, Metcalf JA, DerSimonian R, Orenstein JM, Stevens RA, Falloon J, Polis MA, Lane HC, Sereti I (2003) Incomplete CD4 cell recovery in HIV-1 infection after 12 months of highly antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr 33:125–133CrossRefPubMedGoogle Scholar
  27. 27.
    Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, King A, Lechner F, Spina CA, Little S, Havlir DV, Richman DD, Gruener N, Pape G, Waters A, Easterbrook P, Salio M, Cerundolo V, McMichael AJ, Rowland-Jones SL (2002) Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8:379–385CrossRefPubMedGoogle Scholar
  28. 28.
    Lucas M, Vargas-Cuero AL, Lauer GM, Barnes E, Willberg CH, Semmo N, Walker BD, Phillips R, Klenerman P (2004) Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T cells. J Immunol 172:1744–1753PubMedGoogle Scholar
  29. 29.
    Bürguisser P, Hammann C, Kaufmann D, Battegay M, Rutschmann OT (1999) Expression of the CD28 and CD38 by the CD8+ T lymphocytes in HIV infection correlates with markers of disease severity and changes towards normalization under treatment. Clin Exp Immunol 115:458–463CrossRefGoogle Scholar
  30. 30.
    Landay AL, Spritzler J, Kessler H, Mildvan D, Pu M, Fox L, O’Neil D, Schock B, Kuritzkes D, Lederman MM; AIDS Clinical Trials Group 5014 Team (2003) Immune reconstitution is comparable in antiretroviral-naïve subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen. J Infect Dis 188:1444–1445CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • M. Santin
    • 1
  • M. Mestre
    • 2
  • E. Shaw
    • 1
  • M. J. Barbera
    • 1
  • A. Casanova
    • 3
  • J. Niubo
    • 3
  • F. Bolao
    • 4
  • D. Podzamczer
    • 1
  • F. Gudiol
    • 1
  1. 1.Department of Infectious DiseasesIDIBELL, Hospital Universitari de Bellvitge, University of BarcelonaBarcelonaSpain
  2. 2.Department of ImmunologyIDIBELL, Hospital Universitari de Bellvitge, University of BarcelonaBarcelonaSpain
  3. 3.Department of MicrobiologyIDIBELL, Hospital Universitari de Bellvitge, University of BarcelonaBarcelonaSpain
  4. 4.Department of Internal MedicineIDIBELL, Hospital Universitari de Bellvitge, University of BarcelonaBarcelonaSpain

Personalised recommendations